The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis

The Lancet

Volumn 337, Issue 8739, 1991, Pages 441-446

  The Canadian Cooperative Multiple Sclerosis Study Group, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CANADA; COMBINED MODALITY THERAPY; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MULTIPLE SCLEROSIS; PLASMA EXCHANGE; PREDNISONE; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0025967752     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(91)93389-Q     Document Type: Article

References (35)

1. Rationale for immunomodulating therapies of multiple sclerosis
2. A population-based study of multiple sclerosis in twins
3. Intensive immunosuppression with cyclophosphamide in multiple sclerosis: a follow-up of 110 patients for two to six years
4. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis
5. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH
6. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs
7. Cyclophosphamide in chronic progressive multiple sclerosis maintenance vs nonmaintenance therapy
8. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients
9. IV cyclophosphamide/ACTH plus maintenance cyclophosphamide boosters in progressive MS: intenm report of the Northeast Cooperative MS Treatment Group
10. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis
11. The efficacy and toxicity of cyclosporine A in chronic progressive multiple sclerosis a randomized double-blinded placebo-controlled clinical trial
12. Randomized double blind controlled trial of cyclosporin in multiple sclerosis
13. Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report
14. Immunological treatment of multiple sclerosis I
15. Double-masked trial of azathioprine in multiple sclerosis
16. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis
17. Criteria for the clinical diagnosis of multiple sclerosis
18. New diagnostic criteria for multiple sclerosis: guidelines for research protocols
19. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS)
20. Long-term use of antecubital veins for plasma exchange. The Canadian Cooperative Multiple Sclerosis Study Group
21. Acceptance of placebo-control trial design by progressive multiple sclerosis patients. The Canadian Cooperative Multiple Sclerosis Study Group
22. A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship
23. Non-parametric estimation from incomplete observations
24. Neuroepidemiology. Part II: assessment of therapeutic trials
25. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop
26. Therapeutic plasma exchange
27. Effects of anticancer drugs on the immune system in humans
28. Clinical pharmacology of cancer chemotherapy
29. Experience with cyclophosphamide m multiple sclerosis: the cons
30. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability
31. Spontaneous stabilization in patients with progressive MS
32. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project
33. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial